Piper Jaffray is out with its report today on Watson Pharmaceuticals WPI, raising its PT from $72 to $76.
In a note to clients, Piper Jaffray writes, "With a P/E of only 11x our new 2012 EPS estimate of $5.94 (up from $5.69), and significant potential for double-digit EPS growth beyond
2012, we continue to believe there is plenty of room for value creation. We reiterate our Overweight rating and are raising our PT to $76 from $72."
Shares of WPI closed Monday at $63.55, up 0.54% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CarePharmaceuticalsPiper JaffrayWatson Pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in